AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,647,690 | -2.4% | 546,685 | +0.8% | 0.01% | 0.0% |
| Q2 2023 | $6,813,612 | +89.0% | 542,485 | +66.9% | 0.01% | +100.0% |
| Q1 2023 | $3,604,860 | -4.8% | 325,055 | +4.8% | 0.00% | -25.0% |
| Q4 2022 | $3,787,981 | -23.2% | 310,236 | -34.3% | 0.00% | -20.0% |
| Q3 2022 | $4,932,000 | -3.5% | 472,394 | -0.8% | 0.01% | 0.0% |
| Q2 2022 | $5,112,000 | +21.6% | 476,003 | +7.2% | 0.01% | +25.0% |
| Q1 2022 | $4,204,000 | -13.7% | 443,976 | +3.4% | 0.00% | 0.0% |
| Q4 2021 | $4,871,000 | +29.4% | 429,367 | +163.4% | 0.00% | 0.0% |
| Q4 2020 | $3,764,000 | +15.9% | 163,011 | -29.1% | 0.00% | 0.0% |
| Q3 2020 | $3,248,000 | -6.3% | 230,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $3,468,000 | +70.6% | 230,000 | +4.5% | 0.00% | +33.3% |
| Q1 2020 | $2,033,000 | -5.1% | 220,000 | 0.0% | 0.00% | +50.0% |
| Q4 2019 | $2,143,000 | -14.5% | 220,000 | -29.6% | 0.00% | -33.3% |
| Q3 2019 | $2,505,000 | -39.6% | 312,300 | -6.0% | 0.00% | -40.0% |
| Q2 2019 | $4,147,000 | +45.2% | 332,300 | +58.2% | 0.01% | +66.7% |
| Q1 2019 | $2,856,000 | +60.3% | 210,000 | +12.9% | 0.00% | +50.0% |
| Q4 2018 | $1,782,000 | +13.4% | 186,000 | +43.1% | 0.00% | 0.0% |
| Q3 2018 | $1,572,000 | +11.8% | 130,000 | +44.4% | 0.00% | 0.0% |
| Q2 2018 | $1,406,000 | +55.9% | 90,000 | +50.0% | 0.00% | +100.0% |
| Q1 2018 | $902,000 | -5.1% | 60,000 | -9.1% | 0.00% | 0.0% |
| Q4 2017 | $950,000 | +384.7% | 66,000 | +407.7% | 0.00% | – |
| Q3 2017 | $196,000 | +88.5% | 13,000 | +20.8% | 0.00% | – |
| Q4 2015 | $104,000 | -89.1% | 10,766 | -84.2% | 0.00% | -100.0% |
| Q3 2015 | $951,000 | -10.0% | 67,943 | -9.0% | 0.00% | 0.0% |
| Q2 2015 | $1,057,000 | +61.9% | 74,700 | +24.5% | 0.00% | 0.0% |
| Q1 2015 | $653,000 | -12.7% | 60,000 | -33.3% | 0.00% | 0.0% |
| Q4 2014 | $748,000 | – | 90,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |